Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zelquistinel (AGN-241751) SAD Study in Healthy Volunteers
NCT04981561Phase 1Completed
- Start
- Dec 2016
- Primary completion
- Dec 2017
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Orthosteric Ligands
01
Overview
Phase 1, randomised, double-blind trial of zelquistinel in major depressive disorder (MDD). Primary endpoint: Treatment emergent adverse events at 28 days. Started Dec 2016; status: completed.
02
Drugs
zelquistinel
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04981561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04981561.